Abstract
Fibrosis is a leading cause of mortality. This pressing challenge must be addressed through robust strategies, by developing efficacious anti-fibrotics and by preventing exposure to fibrogenic stimuli. This perspective paper briefly reviews anti-fibrotic and pro-fibrotic botanicals, especially those with inflammation-independent activities, leading to our proposal that future research should focus on efficacy, safety, innovation and good practice. An efficacy-based strategy is put forward for discovering anti-fibrotics; innovative modeling is emphasized for studying both anti-fibrotic therapeutics and pro-fibrotic hazards. At present, with funding insufficient to establish and maintain good practice, botanical research is generally perceived a risky area, but considerable morbidity and mortality risks also exist if we disregard anti- and pro-fibrotic botanicals. Thus, we call for sustainable investment into this challenging but increasingly important research field to encourage innovation, to nurture good practice and bring about breakthroughs.
Original language | English |
---|---|
Pages (from-to) | S19-S20 |
Number of pages | 2 |
Journal | Science |
Volume | 346 |
Issue number | 6216 |
Early online date | 19 Dec 2014 |
DOIs | |
Publication status | Published - 19 Dec 2014 |